左卡尼汀联合促红素对维持性血透患者贫血治疗的临床观察  

Clinical observation of L - camitine combined with recombinant human erythropoietin on the maintenancehemodialysis patients with renal anemia

作　　者：黄珍珍[1] 兰雷[1] 江洁龙[1] 

机构地区：[1]安徽省立医院肾脏内科,安徽合肥230001

出　　处：《中外医学研究》2010年第11期29-30,共2页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的观察左卡尼汀联合重组人红细胞生成素（r—HuEPO）疗法对维持性血透患者贫血的临床疗效和不良反应。方法将52例维持性血液透析患者随机分为观察组和对照组两组，每组26例，观察组给予左卡尼汀及r—HuEPO治疗，对照组给予等容积生理盐水及r—HuEPO治疗，疗程为16周。治疗前、后每4周测定血红蛋白（Hb）、红细胞压积（HCT）和主要生化指标。结果观察组Hb和HCT上升幅度明显高于对照组（P〈0．05）；而且观察组r—HuEPO的每周平均用量较对照组少，两组比较差异有统计学意义（P〈0．05）；同时左卡尼汀注射16周后两组的各项血清生化指标稳定。结论左卡尼汀联合r—HuEPO治疗能有效改善维持性血透患者的肾性贫血，并可降低r—HuEPO不良反应的发生率。Objective Observation of L - camitine on recombinant human erytlropoietin treatment of maintenancehemodialysis patients with renal anemia efficacy and adverse reactions. Methods 52 cases of maintenancehemodialysis patients were randomly divided into observation group and control group,each 26 cases. The observation group was treated by r - HuEPO and L - camitine,the control group was treated by r - HuEPO and equivalence water, totally for 16 weeks. Results Compared with the control group, HCT and Hb were all significantly increased in observation group（ P 〈 0.05 ） ;observation group erythropoietin of average weekly consumption less than that in control group, the difference was statistically significant （P 〈 0. 05 ）. Conclusion Treatment of L - eamitine with recombinant human erythropoietin can significantly improve the efficacy of renal anemia, and can reduce the incidence of r - HuEPO adverse reactions.

关 键 词：重组人促红细胞生成素 左卡尼汀 维持性血液透析 贫血 

分 类 号：R473.1[医药卫生—护理学]